Results 81 to 90 of about 1,989 (180)

Adult Survival in SMA Type 1: A 23‐Year Journey With Home Ventilation and Multidisciplinary Support

open access: yesClinical Case Reports, Volume 14, Issue 3, March 2026.
Diffuse brain atrophy and calvarial hyperostosis in a long‐term survivor of very early onset SMA type 1. ABSTRACT Spinal muscular atrophy (SMA) type 1 is a severe autosomal recessive neuromuscular disorder caused by loss‐of‐function variants in the SMN1 gene, typically leading to death within the first two years without intervention. Long‐term survival
Antonio E. Camelo‐Filho   +4 more
wiley   +1 more source

An Assessment of Genetic Counselors’ Knowledge and Attitudes Regarding Gene Transfer Therapies [PDF]

open access: yes, 2021
Background: There are currently two FDA approved gene transfer therapies, Luxturna (voretigene neparvovec-rzyl) to treat RPE65 Associated Inherited Retinal Dystrophy and Zolgensma (onasemnogene abeparvovec-xioi) to treat Spinal Muscular Atrophy.
Walsh, Chelsey
core  

Atrofia muscular espinal: nuevos paradigmas terapéuticos [PDF]

open access: yes, 2020
La atrofia muscularespinal (AME) es una enfermedad neurodegenerativa de herencia autosómica recesiva,que ocasiona degeneración de las motoneuronas del asta anterior medular,con la consecuente debilidad muscular. Los pacientes con AME tipo
Jiménez Marina, Lorena   +2 more
core   +1 more source

AAV-aMTD-Parkin, a therapeutic gene delivery cargo, enhances motor and cognitive functions in Parkinson's and Alzheimer’s diseases

open access: yesPharmacological Research
Neurodegenerative disorders, such as Parkinson's disease (PD) and Alzheimer's disease (AD), have a global prevalence and profoundly impact both motor and cognitive functions. Although adeno-associated virus (AAV)-based gene therapy has shown promise, its
Seokwon Lee   +9 more
doaj   +1 more source

Improved gene therapy for spinal muscular atrophy in mice using codon-optimized hSMN1 transgene and hSMN1 gene-derived promotor

open access: yesEMBO Molecular Medicine
Physiological regulation of transgene expression is a major challenge in gene therapy. Onasemnogene abeparvovec (Zolgensma®) is an approved adeno-associated virus (AAV) vector gene therapy for infants with spinal muscular atrophy (SMA), however, adverse ...
Qing Xie   +16 more
doaj   +1 more source

Real-World Data in Children with Spinal Muscular Atrophy Type 1 on Long-Term Ventilation Receiving Gene Therapy: A Prospective Cohort Study

open access: yesAdvances in Respiratory Medicine
Patients with spinal muscular atrophy type 1 (SMA-1) requiring invasive ventilation can be eligible for gene therapy if they tolerate at least 8 h off ventilation per day.
Mohammad Ala’ Alajjuri   +3 more
doaj   +1 more source

Kostprijs-plusmodel geeft inzicht in reële prijzen gentherapieën

open access: yes, 2022
Goed nieuws voor patiënten met de zeldzame erfelijke spierziekte spinale musculaire atrofie (SMA) en de zeldzame erfelijke stofwisselingsziekte metachromatische leukodystrofie (MLD).
Ten Ham, Renske M.T.   +4 more
core  

Engineering Targeted Gene Delivery Systems for Primary Hereditary Skeletal Myopathies: Current Strategies and Future Perspectives

open access: yesBiomedicines
Skeletal muscle, constituting ~40% of body mass, serves as a primary effector for movement and a key metabolic regulator through myokine secretion. Hereditary myopathies, including dystrophinopathies (DMD/BMD), limb–girdle muscular dystrophies (LGMD ...
Jiahao Wu   +4 more
doaj   +1 more source

Efficacy and safety of gene therapy with onasemnogene abeparvovec in children with spinal muscular atrophy in the D-A-CH-region: a population-based observational studyResearch in context

open access: yesThe Lancet Regional Health. Europe
Summary: Background: Real-world data on gene addition therapy (GAT) with onasemnogene abeparvovec (OA), including all age groups and with or without symptoms of the disease before treatment are needed to provide families with evidence-based advice and ...
Claudia Weiß   +308 more
doaj   +1 more source

Home - About - Disclaimer - Privacy